arrow
L

Ludwig Kappos

University Hospital Basel
H指数:137
被引数:10.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Macro- and microstructural changes in the upper cervical spinal cord and their clinical correlates in multiple sclerosis

多发性硬化症中上颈椎脊髓的宏观和微观结构变化及其临床相关性

2026-10-090
PRE
Retinal vessel diameters in multiple sclerosis: associations with disability, cardiovascular risk factors and retinal atrophy

多发性硬化患者的视网膜血管直径:与残疾、心血管危险因素和视网膜萎缩的关联

2026-09-280
PRE
Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis

视网膜层预测多发性硬化认知进展,独立于复发活动

2026-08-060
OA
Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years

富马酸非那司提(ponesimod)在复发缓解型多发性硬化(RRMS)中的长期安全性和有效性:来自为期长达13年的随机Ⅱb期CORRE和扩展研究的成果

2026-08-010
PRE
Rethinking prognosis in multiple sclerosis: a multiaxial perspective

重新思考多发性硬化的预后:一种多轴视角

2026-05-190
PRE
Emerging CSF and Serum Biomarkers in Multiple Sclerosis

多发性硬化中新兴的脑脊液和血清生物标志物

2026-05-010
PRE
Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years

临床发病时血清代谢组学特征作为预测多发性硬化活动度和5年后进展的指标

2026-04-260
PRE
Clinical and MRI substrates of Symbol Digit Modalities Test impairment in multiple sclerosis patients with an adult- and late-onset

多发性硬化成年及晚发型患者符号数字模式测试损伤的临床和MRI基础

2026-02-230
PRE
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial

奥匹克单抗在复发型多发性硬化患者中的安全性与有效性(AFFINITY试验第1部分):一项随机、对照的2期临床试验

2025-12-260
PRE
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

奥扎尼妥(ozanimod)在复发型多发性硬化中的长期安全性与有效性:DAYBREAK开放标签扩展试验的最终分析

2025-11-050
OA
TIME: Tractography-Informed myelin estimation

时间:基于 tractography 的髓鞘估计

2025-09-080
OAAI
AI-driven reclassification of multiple sclerosis progression

Ganjgahi, H., Haring, D. A., Aarden, P., Graham, G., Sun, Y., Gardiner, S., Su, W., Berge, C., Bischof, A., Fisher, E., Gaetano, L., Thoma, S. P., Kieseier, B. C., Nichols, T. E., Thompson, A. J., Montalban, X., Lublin, F. D., Kappos, L., Arnold, D. L., … Holmes, C. C. (2025). 人工智能驱动的多发性硬化进展重分类。自然·医学,31(10),3414–3424. [Google Scholar] [CrossRef] [PubMed]

2025-08-200
OAAI
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

血清神经丝轻链在多发性硬化中的研究:年龄和BMI校正的Z分数/百分位数对预测治疗反应优于绝对截断值

2025-08-030
OAAI
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

奥扎尼妥单抗治疗复发型多发性硬化患者的脑萎缩及其与长期残疾和认知功能的关系:来自III期和开放标签扩展试验的结果

2025-07-230
PRE
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial

Ponesimod作为添加治疗在活动性复发多发性硬化患者中的应用(POINT):一项III期、随机、安慰剂对照临床试验

2025-07-130
PRE
Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial

单音弦音乐疗法在多发性硬化症中的应用(“MUTIMS”): <i>一项随机、对照、评估者盲法的试验</i>

2025-07-080
OA
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort

特立氟胺和奥瑞利珠单抗对多发性硬化潜隐性活动比较效果:一项在瑞士多发性硬化队列中的观察性研究

2025-07-020
OAAI